Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes
Conditions:   Diffuse Large B Cell Lymphoma;   Transformed Lymphoma
Interventions:   Other: Handgrip strength test;   Behavioral: Neuropsychological Assessment – Wechsler Test of Adult Reading (WTAR);   Behavioral: Neuropsychological Assessment – Repeatable Battery for the Assessment of Status (RBANS);   Behavioral: Neuropsychological Assessment – Color Trails;   Behavioral: Neuropsychological Assessment -Stroop Color and Word Test;   Behavioral: Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire;   Behavioral: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire;   Behavioral: Quality of Life (EQ-5D-5L) Questionnaire;   Behavioral: PROMIS Cognitive Function 4a Questionnaire;   Behavioral: Comprehensive Score for Financial Toxicity (COST) measure
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Kite, A Gilead Company
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 25, 2020 / by / in
Comments